Introduction
Materials and methods
Design
Setting
Study population
Development of the 14-month patient questionnaire
Data on rehabilitation
Statistical analysis
Results
Responders, n (%) | Non-responders, n (%) | |
---|---|---|
3,439 (69.5) | 1,508 (30.5) | |
Sex | ||
Men | 1,466 (42.6) | 712 (47.2) |
Women | 1,973 (57.4) | 796 (52.8) |
Age (years) | ||
18–39 | 152 (4.4) | 118 (7.8) |
40–49 | 331 (9.6) | 154 (10.2) |
50–59 | 660 (19.2) | 292 (19.4) |
60–69 | 1,263 (36.8) | 419 (27.8) |
70–79 | 802 (23.3) | 338 (22.4) |
80+ | 231 (6.7) | 187 (12.4) |
Cancer diagnoses | ||
Breast | 976 (28.4) | 314 (20.8) |
Prostate | 501 (14.6) | 179 (11.9) |
Colo-rectal | 522 (15.2) | 213 (14.1) |
Gynecological | 230 (6.7) | 120 (7.9) |
Malignant melanoma | 233 (6.8) | 102 (6.8) |
Lung | 188 (5.5) | 113 (7.5) |
Lymphoma | 104 (3.0) | 44 (2.9) |
Head and neck | 125 (3.6) | 81 (5.4) |
Other | 560 (16.2) | 342 (22.7) |
Need for rehabilitation during the 14-month period
Physical area | Emotional area | Family oriented area | Sexual area | Work-related area | Financial area | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n = 3,242 |
n = 3,254 |
n = 3,250 |
n = 3,197 |
n = 1,276 |
n = 1,895 | ||||||||||||||
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | Men n = 1,366 ORadjb (95% CI) | Women n = 1,829 ORadjb (95% CI) |
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) | |
Needs, total | 1,028 (31.7) | − | − | 997 (30.6) | − | − | 453 (13.9) | − | − | 529 (16.6) | − | − | − | 252 (19.8) | − | − | 257 (13.4) | − | − |
Sex | |||||||||||||||||||
Men | 352 (25.4) | 1.00 | 1.00 | 327 (23.5) | 1.00 | 1.00 | 145 (10.4) | 1.00 | 1.00 | 308 (22.5) | 1.00 | − | − | 77 (14.3) | 1.00 | 1.00 | 118 (13.8) | 1.00 | 1.00 |
Women | 676 (36.5) | 1.69** | 1.36** (1.01–1.70) | 670 (35.9) | 1.82** | 1.72** (1.37–2.17) | 308 (16.6) | 1.70** | 1.40* (1.04–1.88) | 221 (12.1) | 0.47** | − | − | 175 (23.7) | 1.87** | 1.55* (1.01–2.39) | 139 (13.4) | 0.97 | 0.86 (0.60–1.25) |
Age (years) | |||||||||||||||||||
18–39 | 54 (36.0) | 1.00 | 1.00 | 82 (54.3) | 1.00 | 1.00 | 47 (31.3) | 1.00 | 1.00 | 34 (22.5) | 1.00 | 1.00 | 1.00 | 23 (22.3) | 1.00 | 1.00 | 20 (16.7) | 1.00 | 1.00 |
40–49 | 149 (46.4) | 1.54* | 1.35 (0.90–2.03) | 176 (53.8) | 0.98 | 0.86 (0.57–1.28) | 96 (29.3) | 0.91 | 0.82 (0.53–1.27) | 77 (23.7) | 1.07 | 0.83 (0.35–2.02) | 0.91 (0.51–1.62) | 73 (32.0) | 1.64 | 1.43 (0.82–2.51) | 51 (19.5) | 1.21 | 1.33 (0.74–2.38) |
50–59 | 263 (41.3) | 1.25 | 1.13 (0.77–1.65) | 279 (43.8) | 0.66* | 0.59** (0.40–0.85) | 135 (21.2) | 0.59** | 0.55** (0.36–0.83) | 133 (21.0) | 0.91 | 0.93 (0.43–1.99) | 0.61 (0.35–1.06) | 116 (28.9) | 1.41 | 1.27 (0.74–2.17) | 97 (19.5) | 1.21 | 1.31 (0.76–2.27) |
60–69 | 339 (27.8) | 0.68* | 0.63* (0.43–0.91) | 304 (25.0) | 0.28** | 0.25** (0.17–0.36) | 117 (9.6) | 0.23** | 0.22** (0.14–0.33) | 203 (17.0) | 0.71 | 0.72 (0.34–1.51) | 0.25** (0.14–0.44) | 32 (9.8) | 0.38** | 0.37** (0.20–0.69) | 66 (10.8) | 0.61 | 0.65 (0.37–1.15) |
70–79 | 172 (23.6) | 0.55** | 0.53** (0.36–0.78) | 125 (17.0) | 0.17** | 0.16** (0.11–0.24) | 48 (6.6) | 0.15** | 0.15** (0.09–0.24) | 69 (9.7) | 0.37** | 0.33** (0.15–0.72) | 0.04** (0.01–0.11) | 6 (3.6) | 0.13** | 0.12** (0.05–0.32) | 18 (5.6) | 0.30** | 0.30** (0.15–0.61) |
80+ | 51 (27.4) | 0.67 | 0.64 (0.39–1.03) | 31 (16.4) | 0.17** | 0.15** (0.09–0.26) | 10 (5.3) | 0.12** | 0.12** (0.06–0.25) | 13 (7.1) | 0.26** | 0.26** (0.10–0.69) | 0.06** (0.01–0.26) | 2 (4.0) | 0.14* | 0.14* (0.03–0.63) | 5 (6.0) | 0.32* | 0.35 (0.12–1.00) |
Cancer diagnosis | |||||||||||||||||||
Breast | 367 (39.5) | 1.00 | 1.00 | 338 (36.2) | 1.00 | 1.00 | 152 (16.3) | 1.00 | 1.00 | 111 (12.1) | 1.00 | − | 1.00 | 94 (23.9) | 1.00 | 1.00 | 62 (11.7) | 1.00 | 1.00 |
Prostate | 96 (20.7) | 0.40** | 0.70* (0.50–0.99) | 89 (19.1) | 0.42** | 1.16 (0.80–1.66) | 30 (6.4) | 0.35** | 0.85 (0.51–1.43) | 159 (34.3) | 3.79** | 2.44** (1.67–3.56) | − | 15 (9.7) | 0.34** | 1.11 (0.52–2.36) | 22 (8.2) | 0.67 | 0.93 (0.49–1.78) |
Colo-rectal | 142 (29.0) | 0.62** | 0.84 (0.65–1.10) | 109 (22.2) | 0.51* | 0.88 (0.66–1.18) | 50 (10.2) | 0.58** | 0.96 (0.66–1.41) | 68 (14.2) | 1.20 | 1.00 | 1.11 (0.65–1.89) | 31 (16.8) | 0.64 | 1.17 (0.69–1.98) | 32 (11.7) | 0.99 | 1.17 (0.70–1.96) |
Gynecological | 69 (31.9) | 0.72* | 0.72* (0.52–0.99) | 79 (36.1) | 0.99 | 1.00 (0.72–1.38) | 43 (19.6) | 1.25 | 1.25 (0.85–1.85) | 41 (19.1) | 1.71** | − | 1.83** (1.21–2.77) | 26 (30.2) | 1.38 | 1.36 (0.80–2.32) | 22 (17.3) | 1.58 | 1.64 (0.96–2.82) |
Malignant melanoma | 49 (22.4) | 0.44** | 0.48** (0.33–0.68) | 51 (23.2) | 0.53** | 0.52** (0.35–0.75) | 19 (8.6) | 0.49** | 0.43* (0.25–0.73) | 16 (7.3) | 0.57* | 0.34** (0.15–0.75) | 0.34** (0.16–0.75) | 8 (8.3) | 0.29** | 0.36* (0.16–0.80) | 13 (10.0) | 0.84 | 0.83 (0.43–1.62) |
Lung | 71 (39.7) | 1.01 | 1.43* (1.01–2.04) | 70 (39.3) | 1.14 | 2.19** (1.52–3.16) | 28 (15.6) | 0.95 | 1.65* (1.03–2.66) | 27 (15.7) | 1.35 | 0.99 (0.53–1.84) | 1.53 (0.74–3.16) | 8 (15.7) | 0.59 | 1.09 (0.47–2.54) | 18 (17.1) | 1.56 | 2.00* (1.07–3.75) |
Lymphoma | 35 (34.3) | 0.80 | 0.92 (0.59–1.44) | 49 (48.0) | 1.63* | 2.24 **(1.42–3.51) | 24 (23.8) | 1.60 | 1.90* (1.12–3.23) | 15 (15.0) | 1.28 | 0.87 (0.40–1.87) | 0.76 (0.29–2.02) | 9 (19.6) | 0.78 | 0.93 (0.41–2.10) | 11 (16.2) | 1.46 | 1.39 (0.67–2.91) |
Head and neck | 32 (26.9) | 0.56** | 0.69 (0.43–1.09) | 39 (33.3) | 0.88 | 1.29 (0.82–2.04) | 15 (12.9) | 0.76 | 0.97 (0.52–1.80) | 12 (10.4) | 0.84 | 0.31** (0.13–0.72) | 1.49 (0.54–4.11) | 14 (25.5) | 1.09 | 1.57 (0.74–3.32) | 12 (15.0) | 1.33 | 1.20 (0.58–2.50) |
Other | 167 (31.9) | 0.72** | 0.92 (0.70–1.20) | 173 (32.9) | 0.87 | 1.29 (0.98–1.70) | 92 (17.6) | 1.09 | 1.42* (1.01–2.02) | 80 (15.4) | 1.32 | 0.81 (0.52–1.25) | 1.07 (0.64–1.78) | 47 (22.5) | 0.93 | 1.38 (0.84–2.28) | 65 (20.8) | 1.99 | 2.03** (1.28–3.22) |
Participation in rehabilitation activities
One or more activities | One or more physical activities | One or more psychological activities | One or more work-related/financial activities | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n = 3,257 |
n = 3,439 |
n = 3,439 |
n = 3,439 | |||||||||
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) | |
Participation, total | 1,697 (52.1) | − | − | 1,447 (42.1) | − | − | 586 (17.0) | − | − | 403 (11.7) | − | − |
Sex | ||||||||||||
Men | 545 (39.4) | 1.00 | 1.00 | 438 (29.9) | 1.00 | 1.00 | 152 (10.4) | 1.00 | 1.00 | 134 (9.1) | 1.00 | 1.00 |
Women | 1,152 (61.5) | 2.46** | 1.54** (1.25–1.90) | 1009 (51.1) | 2.46** | 1.41** (1.14–1.73) | 434 (22.0) | 2.44** | 1.90** (1.43–2.52) | 269 (13.6) | 1.56** | 1.03 (0.74–1.43) |
Age (years) | ||||||||||||
18–39 | 102 (67.1) | 1.00 | 1.00 | 68 (44.7) | 1.00 | 1.00 | 63 (41.5) | 1.00 | 1.00 | 55 (36.2) | 1.00 | 1.00 |
40–49 | 234 (72.2) | 1.27 | 0.88 (0.57–1.37) | 197 (59.5) | 1.82** | 1.29 (0.85–1.96) | 118 (35.6) | 0.78 | 0.59* (0.39–0.89) | 87 (26.3) | 0.63* | 0.50** (0.32–0.78) |
50–59 | 443 (69.7) | 1.13 | 0.81 (0.54–1.22) | 344 (52.1) | 1.34 | 1.02 (0.70–1.50) | 184 (27.9) | 0.55** | 0.42** (0.29–0.63) | 163 (24.7) | 0.58** | 0.48** (0.32–0.72) |
60–69 | 600 (49.6) | 0.48** | 0.34** (0.23–0.51) | 546 (43.2) | 0.94 | 0.74 (0.51–1.08) | 154 (12.2) | 0.20** | 0.16** (0.11–0.24) | 71 (5.6) | 0.11** | 0.09** (0.06–0.13) |
70–79 | 257 (34.7) | 0.26** | 0.21** (0.14–0.32) | 238 (29.7) | 0.52** | 0.48** (0.33–0.71) | 53 (6.6) | 0.10** | 0.09** (0.06–0.14) | 19 (2.4) | 0.04** | 0.04** (0.02–0.07) |
80+ | 61 (31.4) | 0.22** | 0.18** (0.11–0.29) | 54 (23.4) | 0.38** | 0.34** (0.21–0.55) | 14 (6.1) | 0.10** | 0.08** (0.04–0.15) | 8 (3.5) | 0.06** | 0.05** (0.02–0.12) |
Cancer diagnosis | ||||||||||||
Breast | 694 (73.9) | 1.00 | 1.00 | 652 (66.8) | 1.00 | 1.00 | 239 (24.5) | 1.00 | 1.00 | 152 (15.6) | 1.00 | 1.00 |
Prostate | 163 (35.0) | 0.19** | 0.41** (0.30–0.57) | 139 (27.7) | 0.19** | 0.34** (0.25–0.47) | 34 (6.8) | 0.22** | 0.77 (0.47–1.24) | 23 (4.6) | 0.26** | 0.65 (0.36–1.17) |
Colo-rectal | 192 (39.8) | 0.23** | 0.36** (0.27–0.47) | 149 (28.5) | 0.20** | 0.28** (0.22–0.36) | 70 (13.4) | 0.48** | 0.91 (0.65–1.27) | 47 (9.0) | 0.54** | 0.84 (0.56–1.27) |
Gynecological | 107 (47.8) | 0.32** | 0.31** (0.23–0.42) | 78 (33.9) | 0.26** | 0.25** (0.19–0.34) | 47 (20.4) | 0.79 | 0.76 (0.53–1.11) | 30 (13.0) | 0.81 | 0.77 (0.49–1.21) |
Malignant melanoma | 71 (32.3) | 0.17** | 0.16** (0.11–0.22) | 52 (22.3) | 0.14** | 0.16** (0.11–0.22) | 25 (10.7) | 0.37** | 0.32** (0.20–0.52) | 12 (5.2) | 0.29** | 0.20** (0.10–0.38) |
Lung | 93 (52.0) | 0.38** | 0.62** (0.43–0.89) | 75 (39.9) | 0.33** | 0.46** (0.33–0.65) | 31 (16.5) | 0.61* | 1.22 (0.78–1.92) | 15 (8.0) | 0.47** | 0.82 (0.44–1.50) |
Lymphoma | 54 (54.0) | 0.41** | 0.47** (0.30–0.74) | 45 (43.3) | 0.38** | 0.44** (0.28–0.67) | 25 (24.0) | 0.98 | 1.24 (0.74–2.08) | 30 (28.9) | 2.20** | 2.36** (1.39–4.03) |
Head and neck | 69 (58.5) | 0.50* | 0.65 (0.42–1.01) | 54 (43.2) | 0.38** | 0.49** (0.32–0.74) | 27 (21.6) | 0.85 | 1.35 (0.81–2.25) | 11 (8.8) | 0.52* | 0.49* (0.24–0.99) |
Other | 254 (48.0) | 0.33** | 0.44** (0.33–0.57) | 203 (36.3) | 0.28** | 0.37** (0.29–0.48) | 88 (15.7) | 0.57** | 0.83 (0.60–1.15) | 83 (14.8) | 0.94 | 1.01 (0.69–1.47) |
Unmet rehabilitation needs after 14 months
Physical area | Emotional area | Family oriented area | Sexual area | Work-related area | Financial area | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n = 922 |
n = 883 |
n = 380 |
n = 454 |
n = 222–230 |
n = 230 | |||||||||||||
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) |
n (%) | ORcrude | ORadja (95% CI) | |
Unmet needs, total | 159 (17.3) | − | − | 209 (23.7) | − | − | 122 (32.1) | − | − | 225 (49.6) | − | − | 43 (18.7) | − | − | 79 (34.4) | − | − |
Sex | ||||||||||||||||||
Men | 63 (19.8) | 1.00 | 1.00 | 85 (31.1) | 1.00 | 1.00 | 43 (34.4) | 1.00 | 1.00 | 124 (46.8) | 1.00 | 1.00 | 18 (26.1) | 1.00 | 1.00 | 42 (39.3) | 1.00 | 1.00 |
Women | 96 (15.9) | 0.76 | 0.96 (0.60–1.54) | 124 (20.3) | 0.56** | 0.58** (0.37–0.92) | 79 (31.0) | 0.86 | 1.06 (0.58–1.93) | 101 (53.4) | 1.31 | 0.80 (0.42–1.55) | 25 (15.5) | 0.52 | 0.53 (0.19–1.47) | 37 (30.1) | 0.67 | 0.53 (0.24–1.19) |
Age (years) | ||||||||||||||||||
<60 | 64 (15.3) | 1.00 | 1.00 | 91 (18.3) | 1.00 | 1.00 | 65 (26.9) | 1.00 | 1.00 | 105 (47.7) | 1.00 | 1.00 | 33 (16.6) | 1.00 | 1.00 | 53 (33.3) | 1.00 | 1.00 |
≥60 | 95 (18.9) | 1.29 | 1.17 (0.81–1.70) | 118 (30.7) | 1.98** | 2.05** (1.47–2.85) | 57 (41.3) | 1.92** | 2.03** (1.27–3.25) | 120 (51.3) | 1.15 | 1.83** (1.16–2.89) | 10 (32.3) | 2.40* | 2.98* (1.14–7.80) | 26 (36.6) | 1.16 | 1.08 (0.58–2.03) |
Cancer diagnosis | ||||||||||||||||||
Breast | 40 (12.1) | 1.00 | 1.00 | 55 (17.7) | 1.00 | 1.00 | 33 (26.4) | 1.00 | 1.00 | 54 (56.8) | 1.00 | 1.00 | 12 (14.1) | 1.00 | 1.00 | 19 (38.0) | 1.00 | 1.00 |
Prostate | 16 (18.4) | 1.63 | 1.46 (0.65–3.27) | 24 (30.8) | 2.06* | 0.94 (0.45–1.97) | 7 (28.0) | 1.08 | 0.83 (0.26–2.62) | 51 (36.4) | 0.44** | 0.24** (0.10–0.56) | 2 (15.4) | 1.11 | 0.30 (0.04–2.35) | 10 (55.6) | 2.04 | 1.06 (0.27–4.13) |
Colo-rectal | 28 (22.1) | 2.05** | 1.93* (1.07–3.48) | 18 (19.6) | 1.13 | 0.78 (0.41–1.49) | 16 (38.1) | 1.72 | 1.62 (0.72–3.68) | 29 (48.3) | 0.71 | 0.52 (0.23–1.17) | 4 (14.8) | 1.06 | 0.55 (0.13–2.36) | 6 (23.1) | 0.49 | 0.32 (0.09–1.08) |
Gynecological | 14 (24.6) | 2.36* | 2.33* (1.17–4.65) | 17 (23.9) | 1.46 | 1.47 (0.79–2.74) | 10 (30.3) | 1.21 | 1.16 (0.49–2.72) | 16 (48.5) | 0.71 | 0.68 (0.30–1.52) | 5 (19.2) | 1.45 | 1.45 (0.45–4.62) | 6 (28.6) | 0.65 | 0.65 (0.21–1.96) |
Malignant melanoma | 4 (9.8) | 0.78 | 0.75 (0.25–2.26) | 17 (37.8) | 2.81** | 2.51* (1.24–5.05) | 5 (31.3) | 1.27 | 1.29 (0.40–4.13) | 8 (72.7) | 2.02 | 1.68 (0.40–6.99) | 0 (0) | − | − | 3 (23.1) | 0.49 | 0.31 (0.07–1.46) |
Lung | 15 (22.7) | 2.13* | 1.97 (0.97–4.01) | 16 (28.6) | 1.85 | 1.31 (0.66–2.60) | 10 (40.0) | 1.86 | 1.46 (0.57–3.72) | 14 (66.7) | 1.52 | 1.13 (0.39–3.27) | 4 (50.0) | 6.08* | 4.02 (0.75–21.7) | 7 (43.8) | 1.27 | 0.86 (0.25–3.02) |
Lymphoma | 7 (21.9) | 2.03 | 1.95 (0.76–5.00) | 15 (34.1) | 2.39* | 2.05 (0.99–4.27) | 9 (40.9) | 1.93 | 2.19 (0.81–5.89) | 8 (53.3) | 0.87 | 0.72 (0.22–2.36) | 2 (22.2) | 1.74 | 1.65 (0.29–9.26) | 4 (36.4) | 0.93 | 0.69 (0.17–2.88) |
Head and neck | 9 (32.1) | 3.43** | 3.32** (1.34–8.22) | 13 (35.1) | 2.51* | 2.00 (0.90–4.43) | 6 (42.9) | 2.09 | 2.09 (0.64–6.85) | 7 (63.6) | 1.33 | 1.24 (0.32–4.81) | 4 (28.6) | 2.43 | 1.63 (0.36–7.29) | 6 (50.0) | 1.63 | 0.97 (0.23–4.10) |
Other | 26 (16.9) | 1.47 | 1.41 (0.77–2.57) | 34 (22.7) | 1.36 | 0.98 (0.56–1.72) | 26 (33.3) | 1.39 | 1.48 (0.72–3.04) | 38 (55.9) | 0.96 | 0.77 (0.35–1.69) | 10 (25.0) | 2.03 | 1.25 (0.39–4.05) | 18 (28.6) | 0.65 | 0.43 (0.16–1.13) |